Aptamer Group plc, a developer of synthetic antibody alternatives, has announced two new development contracts for its Optimer binders and a licensing heads of terms agreement with a global specialty enzyme provider. The developments signal continued momentum for the company’s Optimer platform in enzyme modulation and small molecule recognition for research and diagnostic applications. The first of the new development contracts involves the creation of additional enzyme-modulating Optim...